

Madrid, June 12, 2026

Making Science Group, S.A. (hereinafter, "Making Science" or the "Company"), pursuant to Article 17 of Regulation (EU) No. 596/2014 on market abuse, Article 227 of Law 6/2023, of March 17, on Securities Markets and Investment Services, and related provisions, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity ("BME Growth"), hereby announces the following:

OTHER RELEVANT INFORMATION

On June 11, 2026, at 9:00 a.m. (Madrid time), the Ordinary General Shareholders' Meeting of the Company was held at the Company's registered office, with shareholders representing 64.416% of the Company's voting share capital present or duly represented.

At the meeting, the matters included on the agenda contained in the notice of meeting published on the BME Growth website as "Other Relevant Information" on May 8, 2026, and simultaneously on the Company's corporate website, were submitted for discussion and vote. The following resolutions were adopted with the voting majorities indicated below:

FIRST

Review and approval, as appropriate, of the Company's Annual Financial Statements, including the Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement and Notes thereto, together with the Management Report, for the fiscal year ended December 31, 2025.

Approved unanimously.

SECOND

Review and approval, as appropriate, of the proposed allocation of profit for the fiscal year ended December 31, 2025.

It is noted that, at the General Shareholders' Meeting held on March 20, 2026, the Company approved the payment of an interim dividend against 2025 earnings in the amount of **€2,000,000**, which was duly paid.

Basis of Allocation	Amount
Profit of the year	+5.154.710 euros
Allocation:	
Dividends (equal to interim dividend paid))	2.000.000 euros
Voluntary reserves	3.154.490 euros
Legal reserve	220 euros
Total	5.154.710 euros

Approved unanimously.



THIRD

Review and approval, as appropriate, of the Group's Consolidated Financial Statements, including the Consolidated Balance Sheet, Consolidated Income Statement, Consolidated Statement of Changes in Equity, Consolidated Cash Flow Statement and Notes thereto, together with the Consolidated Management Report, for the fiscal year ended December 31, 2025.

Approved unanimously.

FOURTH

Review and approval, as appropriate, of the Non-Financial Information Statement for fiscal year 2025.

Approved by majority vote.

FIFTH

Review and approval, as appropriate, of the management activities carried out by the Board of Directors during the fiscal year ended December 31, 2025.

Approved by majority vote.

SIXTH

Appointment of Grant Thornton as statutory auditor of the Company and of the Group's consolidated financial statements for the fiscal year ending December 31, 2026.

Approved by majority vote.

SEVENTH

Approval, as appropriate, of the remuneration policy for the Board of Directors and executive directors for fiscal year 2026, as well as the maximum aggregate annual remuneration of all members of the Board of Directors, in accordance with the Company's Bylaws and the Spanish Companies Act, in an amount of **€1,300,000 per year**.

Approved by majority vote.

EIGHTH

Delegation of powers.

Approved by majority vote.

NINTH

Preparation, reading and approval, as appropriate, of the minutes of the meeting.

Approved by majority vote.



In compliance with the provisions of Circular 3/2020 of BME MTF Equity, the Company expressly states that the information contained herein has been prepared under the sole responsibility of the Company and its currently serving directors.

Yours faithfully,

José Antonio Martínez Aguilar
Chief Executive Officer
Making Science Group, S.A.